Oculis (NASDAQ:OCS) Reaches New 12-Month High – Should You Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $16.87 and last traded at $16.09, with a volume of 4021 shares traded. The stock had previously closed at $15.80.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Wednesday, October 23rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.20.

Oculis Trading Up 7.1 %

The business has a 50-day moving average price of $12.97 and a two-hundred day moving average price of $12.25. The company has a market cap of $685.33 million, a P/E ratio of -8.88 and a beta of 0.30. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. The business had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. On average, analysts predict that Oculis Holding AG will post -2.19 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.